Sutro Biopharma
STRO
Market cap $291M

3.55 USD

-0.09

2.47%

Updated Oct 22, 10:49 AM EDT

1 day

-2.47%

5 days

-8.27%

1 month

-1.11%

3 months

-11.03%

6 months

-5.84%

Year to date

-22.32%

1 year

20.34%

5 years

-79.24%

About: Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Employees: 304

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

107% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 28

11% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 19

2% more funds holding

Funds holding: 117 [Q1] → 119 (+2) [Q2]

9.19% less ownership

Funds ownership: 86.42% [Q1] → 77.23% (-9.19%) [Q2]

39% less capital invested

Capital invested by funds: $305M [Q1] → $185M (-$120M) [Q2]

99% less call options, than puts

Call options by funds: $1K | Put options by funds: $91K

100% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 0 (-3) [Q2]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$11

210%

upside

Avg. target

$13.17

271%

upside

High target

$17

379%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

Piper Sandler Edward Tenthoff 34% 1-year accuracy 13 / 38 met price target	210%upside $11	Overweight Reiterated	11 Oct 2024
HC Wainwright & Co. Andrew Fein 49% 1-year accuracy 62 / 126 met price target	238%upside $12	Buy Reiterated	11 Oct 2024
JMP Securities Reni Benjamin 21% 1-year accuracy 6 / 28 met price target	379%upside $17	Market Outperform Reiterated	16 Sept 2024
HC Wainwright & Co. Andrew Fein 49% 1-year accuracy 62 / 126 met price target	238%upside $12	Buy Reiterated	16 Sept 2024
Truist Securities Asthika Goonewardene 75% 1-year accuracy 12 / 16 met price target	323%upside $15	Buy Maintained	16 Aug 2024

See Analyst Rankings

Financial journalist opinion

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Proprietary cell-free platform enables the design of next-generation ADCs intended to broaden addressable patient populations

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

STRO specializes in ADCs for oncology, leveraging XpressCF and XpressCF+ platforms for precise antibody-drug conjugates without living cells. STRO-002, a promising ADC for ovarian cancer, has shown favorable safety and efficacy in trials, with potential FDA approval by 2026-2027. Collaborations with Merck, Vaxcyte, and Astellas Pharma could generate up to $3 billion in milestone payments.

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody-drug conjugates (ADCs), today announced that on September 16, 2024, the Compensation Committee of Sutro's Board of Directors granted 60,000 restricted stock units (RSUs) of Sutro common stock to a new employee. The grant was made as an inducement material to the employee's acceptance of employment with Sutro and was approved by the Compensation Committee of Sutro's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian cancer and was selected to be the recommended phase 2 dose (RP2D) -

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a Research Forum to highlight its pipeline of next-generation ADCs. The live webcast will be held on Thursday, October 10, 2024, starting at 1:30 p.m. PT / 4:30 p.m. ET.

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

Zacks Investment Research

Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why

Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer.

Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that REFRαME-L1, the global Phase 2 study of luveltamab tazevibulin (luvelta) for patients with non-small cell lung cancer (NSCLC) whose tumor expresses Folate Receptor-α (FRα), has been initiated and is open for enrollment. Initial data from this study is expected in the first half of 2025.

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Zacks Investment Research

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.64 per share a year ago.

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

- Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025 -

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline

CONROE, Texas , June 3, 2024 /PRNewswire/ -- VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and RNA medicines, has entered into a strategic partnership with Sutro Biopharma, Inc. (Sutro) to support clinical production of luveltamab tazevibulin, abbreviated as "luvelta", a novel Folate Receptor-α (FRα)-targeting antibody-drug conjugate (ADC) with the potential to address the unmet need in several FRα-expressing cancers. Sutro, a clinical-stage oncology company pioneering site-specific and novel-format ADCs, has just initiated the randomized portion (Part 2) of REFRαME-O1, a global, registration-directed clinical trial of luvelta (NCT05870748) in platinum-resistant ovarian cancer (PROC).

VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline

See News Rankings

Charts implemented using Lightweight Charts™